Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience-Reference-Cited by-同舟云学术

Subsequent attempt tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia; a single institute experience

Published:2021-06-11 Issue:4 Volume:39 Page:549-557
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Ureshino Hiroshi¹^ORCID,Kamachi Kazuharu¹^ORCID,Nishioka Atsujiro¹,Okamoto Sho¹,Katsuya Hiroo¹,Yoshimura Mariko¹,Kubota Yasushi¹,Ando Toshihiko¹,Kimura Shinya¹

Affiliation:

1. Division of Hematology, Respiratory Medicine and Oncology Department of Internal Medicine Faculty of Medicine Saga University Saga Japan

Funder

Okinaka Memorial Institute for Medical Research

Japan Society for the Promotion of Science

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.2896

Reference26 articles.

1. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

2. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

3. Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial

4. Treatment-free remission after first-line dasatinib discontinuation in patients with chronic myeloid leukaemia (first-line DADI trial): a single-arm, multicentre, phase 2 trial

5. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety;Expert Opinion on Drug Safety;2024-06-17

2. Treatment-Free Remission in Chronic Myeloid Leukemia;Journal of Clinical Medicine;2024-04-27

3. Computational modeling reveals key factors driving treatment-free remission in chronic myeloid leukemia patients;npj Systems Biology and Applications;2024-04-27

4. Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib – interim results from the DAstop2 trial;Leukemia;2024-01-26

5. Second Treatment-Free Remission Attempt in Patients with Chronic Myeloid Leukemia;Clinical Lymphoma Myeloma and Leukemia;2023-12